DUBLIN, Ireland — Alkermes plc (Nasdaq: ALKS) today announced topline results from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI® (olanzapine and samidorphan) in patients with schizophrenia, schizophreniform disorder or bipolar I disorder for up to four years of treatment, following treatment...
research News
Seattle, WA — With pediatric inflammatory bowel disease (IBD) diagnoses on the rise globally, a clinical trial in Seattle aims to transform treatment approaches through deep molecular profiling. Recruitment has begun for the Seattle STRIDE study, a joint effort by Seattle Children’s Research Institute and the Allen Institute for Immunology....
Chicago, Illinois – Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. The Alliance for Clinical Trials in Oncology today announced positive results from the phase III AMBASSADOR (A031501) trial for the adjuvant treatment of patients with localized muscle-invasive urothelial...
SOUTH SAN FRANCISCO, Calif. — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases, announced that it has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical...
In a recent study, patients with myelodysplastic syndrome (MDS) who have myelofibrosis (MF) showed a worse prognosis when MF was of greater severity. However, this pattern of severity influencing prognosis appeared negated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study findings were reported in the journal Experimental Hematology & Oncology....
The brain is indeed a target for treating ALS (amyotrophic lateral sclerosis), Northwestern Medicine scientists have discovered. This flips a long-standing belief that the disease starts in the spinal motor neurons and any therapy would need to target the spine as the key focus. A new Northwestern study shows the degeneration...
New York, NY – Researchers at the Icahn School of Medicine at Mount Sinai have made a significant breakthrough in Alzheimer’s disease research by identifying a novel way to potentially slow down or even halt disease progression. The study, which focuses on the role of reactive astrocytes and the plexin-B1...
REYKJAVIK, Iceland — Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a confirmatory clinical study for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept). “The progress of our product pipeline clearly illustrates the advantage of our...
Luxembourg – In a new position paper, and following engagement with its national members and the European Working Group of People with Dementia (EWGPWD), Alzheimer Europe calls for concrete actions to enable timely, safe and equitable access to anti-amyloid drugs, for patients who are most likely to benefit from these...
Saarbrücken, Germany – New insights into the pathogenesis of Alzheimer’s disease could unlock novel therapeutic approaches and help to prevent the disease. A study led by Professors Marcus Grimm and Tobias Hartmann at the Rhineland Campus of the SRH University of Applied Health Sciences in Leverkusen and at Saarland University...